Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

GSK3α has been identified as a new target in the treatment of acute myeloid leukemia (AML). However, most GSK3 inhibitors lack specificity for GSK3α over GSK3β and other kinases. We have previously shown in lung cancer cells that GSK3α and to a lesser extent GSK3β are inhibited by the advanced clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuenzi, Brent M., Remsing Rix, Lily L., Kinose, Fumi, Kroeger, Jodi L., Lancet, Jeffrey E., Padron, Eric, Rix, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345777/
https://www.ncbi.nlm.nih.gov/pubmed/30679640
http://dx.doi.org/10.1038/s41598-018-37174-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345777/
https://www.ncbi.nlm.nih.gov/pubmed/30679640
http://dx.doi.org/10.1038/s41598-018-37174-6

Ejemplares similares